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Available online 6 January 2016Nanomedicines have signiﬁcant potential for cancer treatment. Although themajority of nanomedicines current-
ly tested in clinical trials utilize simple, biocompatible liposome-based nanocarriers, their widespread use is lim-
ited by non-speciﬁcity and low target site concentration and thus, do not provide a substantial clinical advantage
over conventional, systemic chemotherapy. In the past 20 years, we have identiﬁed speciﬁc receptors expressed
on the surfaces of tumor endothelial and perivascular cells, tumor cells, the extracellular matrix and stromal cells
using combinatorial peptide libraries displayed on bacteriophage. These studies corroborate the notion that
unique receptor proteins such as IL-11Rα, GRP78, EphA5, among others, are differentially overexpressed in
tumors and present opportunities to deliver tumor-speciﬁc therapeutic drugs. By using peptides that bind to
tumor-speciﬁc cell-surface receptors, therapeutic agents such as apoptotic peptides, suicide genes, imaging
dyes or chemotherapeutics can be precisely and systemically delivered to reduce tumor growth in vivo, without
harming healthy cells. Given the clinical applicability of peptide-based therapeutics, targeted delivery of
nanocarriers loaded with therapeutic cargos seems plausible. We propose a modular design of a functionalized
protocell in which a tumor-targeting moiety, such as a peptide or recombinant human antibody single chain
variable fragment (scFv), is conjugated to a lipid bilayer surrounding a silica-based nanocarrier core containing a
protected therapeutic cargo. The functionalized protocell can be tailored to a speciﬁc cancer subtype and treatment
regimen by exchanging the tumor-targeting moiety and/or therapeutic cargo or used in combination to create
unique, theranostic agents. In this review, we summarize the identiﬁcation of tumor-speciﬁc receptors through
combinatorial phage display technology and the use of antibody display selection to identify recombinant human
scFvs against these tumor-speciﬁc receptors. We compare the characteristics of different types of simple and com-
plex nanocarriers, and discuss potential types of therapeutic cargos and conjugation strategies. Themodular design
of functionalized protocells may improve the efﬁcacy and safety of nanomedicines for future cancer therapy.
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Limitations of conventional cancer drug efﬁcacy include insolubility,
systemic toxicity and drug resistance compounded by debilitating side
effects such as nausea, fatigue, neuropathy, and organ failure. An effec-
tive solution to circumvent these limitations is to deliver cancer drugs
within biocompatible nanocarriers. Simple nanocarriers span diverse
materials such as magnetic or colloidalmetals, carbon-based structures,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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size, shape, loading capacity, payload release, stability, retention and
clearance from the body, which impose further restrictions on their ef-
ﬁcacy as cancer therapeutics. For example, nanocarrier size is a critical
determining parameter since particle sizes b5 nm are cleared in the
urine [1] although particles up to 50 nm have been detected as well,
and nanoparticles N100 nm are cleared by the mononuclear phagocyte
system (MPS), respectively. Ideally, an optimally loaded nanocarrier
would be stable in the circulation to protect and deliver its therapeutic
cargo to the target site, have good penetrance and retention within
the target site so thatmeasured cargo release occurs within a therapeu-
tic window, and ultimately be organically cleared to prevent toxicity
from long-term accumulation [2]. By combining features from simple
nanocarriers, complex nanocarriers have improved biocharacteristics
so that delivery of cancer therapeutics is clinically efﬁcacious.
Although nanocarrier technology has improved, their lack of target
speciﬁcity limits their widespread use. In solid tumors however, large
fenestrations at endothelial cell borders and numerous, loose pericyte
attachments are characteristic of rapidly growing tumor blood vessels
that allow nanocarriers to passively exit the circulation within tumors
and accumulate non-speciﬁcally [3–5]. This phenomenon is referred to
as the enhanced permeability and retention (EPR) effect [6,7]. Never-
theless, the EPR effect does not signiﬁcantly increase payload concentra-
tions at the target site and in fact, increased circulation times dissipate
accumulation [8]. So, how could nanocarrier targeting and retention
be improved for efﬁcacious tumor treatment?
Since 1996, we and others have used, modiﬁed and adapted in vivo
and in vitro phage display to identify ligand-receptor or scFv–epitope
pairs as ameans to speciﬁcally deliver a covalently linked apoptotic pep-
tide, chemotherapeutic drug, reporter or suicide gene or imaging agents
directly to tumors by intravenous administration [9–30]. Unlike other
targeting moieties, peptides identiﬁed by in vivo phage display bind
only to physiologically accessible receptors and, depending on the selec-
tion constraints, can enrich for targeting moieties that are internalized
into cells subsequent to ligand binding. Thus, functional selection of
targeting peptides embedded within the experimental design circum-
vents issues such as the EPR effect and non-speciﬁc uptake and obviates
the need to reassess internalization of tumor-targeted therapeutics
during downstream drug development. Additionally, depending on
receptor location, i.e., tumor vs. tumor endothelial cells, internalization
of nanomedicines will minimize or maximize, respectively, their distri-
bution within the tumor via the bystander effect [31]. Off-target effects
are minimized by using targeted liposomes loaded with doxorubicin
to treat neuroblastoma [32–35]. Targeting liposomal doxorubicin to
cultured human breast cancer or pancreatic adenocarcinoma cells is
improved by inserting different targeting peptides puriﬁed as fusion
proteins of the bacteriophage pVIIImajor coat proteins [36]. Consequent-
ly, one could envision a modular design of a targeted, stable complex
nanocarrier consisting of a peptide ligand or monoclonal antibody
targeting moiety conjugated to the lipid bilayer coated mesoporous
silica nanocarrier, termed a functionalized protocell, which can speciﬁ-
cally deliver a protected therapeutic cargo intravenously or locally by
peritumor injection or inhalation. The term protocell (also known as
a protobiont) is utilized in evolutionary biology to describe a self-
organized spherical collection of lipids proposed as a stepping-stone to
the creation of life. In the context of nanomedicine (and throughout
this review) we use the term protocell to refer to a cell-like nanocarrier
composed of a high surface area mesoporous silica nanoparticle core
enveloped within a supported lipid bilayer [37–39]. In this construct,
the core can be loaded with high concentrations of disparate cargos.
The lipid bilayer serves to seal and protect the cargo and provides a bio-
compatible interface that can be conjugated with polymers to enhance
stability and peptides or antibodies to direct speciﬁc targeting and intra-
cellular trafﬁcking.
The modular design of functionalized protocells will permit the
targeting moiety to be exchanged depending on the tumor of interest.For instance, the targeting moiety can be a peptide or antibody-like
moiety such as a single chain variable fragment (scFv) that binds to
overexpressed receptor proteins such as interleukin-11 receptor alpha
(IL-11Rα) [23,40–42], or the 78-kDa glucose-regulated protein (GRP78)
[43–47] in prostate or breast tumors. EphA5would be an appropriate sur-
face receptor to target in non-small cell lung tumors due to its high ex-
pression [18,29]. scFvs that exhibit distinct receptor afﬁnities or bind to
different epitopes can be used as the binding moiety to elicit a speciﬁc
therapeutic effect. For example, scFvs can be used to inhibit or modulate
receptor function or act synergistically with the delivered therapeutic
cargo [48]. Alternatively, binding of the functionalized protocell can elicit
receptor internalization for cargo release within the cell. Table 1 lists
targeting peptide ligands that have been identiﬁed by in vivo and/or
in vitro phage display, whereby binding to their target receptor elicits
receptor-mediated internalization.
Other examples of targeting peptides include tumor-targeting
peptides derived from luteinizing hormone/chorionic gonadotropin
conjugated to membrane-disrupting lytic peptides to effectively inhibit
human breast and prostate xenograft tumor growth and metastases
[49–52]. In addition to peptides or antibodies, aptamers, short, single
stranded RNA or DNA oligonucleotides, have been developed for
targeted cancer therapy to treat a variety of tumors in clinical trials by
delivering intercalated chemotherapeutics or conjugated directly to
nanocarriers containing therapeutic cargos (reviewed in [53,54]). Com-
binations of aptamers containing intercalated doxorubicin or a NF-κB
decoywere effectively used in vitro to inhibit growthof cultured pancre-
atic tumor cells by inhibiting nuclear translocation of NF-κB [55].
Similar to chemotherapeutic drugs, targeted therapies are designed
to inhibit tumor growth via a dynamic, progressive process. This en-
sures that toxic cellular byproducts are within physiological limits that
can be effectively cleared. Due to the leakiness of tumor blood vessels,
there is no doubt that targeted nanocarriers will accumulate in tumors
partly due to the EPR effect. Nevertheless, once passive accumulation
of targeted nanoparticles occurs, speciﬁc binding to tumor-speciﬁc
receptors, internalization and retention in cells within the tumor micro-
environment will ensure effective cargo release and higher, localized
therapeutic indices with decreased systemic, collateral damage. Targeted
delivery of functionalized protocells may also circumvent problems asso-
ciated with “binding site inhibition” as this model does not take into ac-
count variability in receptor concentrations or turnover at the tumor
site [56]. For instance, unless locally administered, intravenous infusion
of targeted nanomedicines will be diluted in the circulation so that target
site accumulation occurs over time. Unlike passive accumulation, targeted
therapies, by deﬁnition, can be administered at lower doses due to their
increased, effective concentration at the target site as conﬁrmed both
experimentally and bymodeling and simulation [37,38,57]. Furthermore,
functionalized protocells have a high cargo loading capacity, so that
saturating receptor concentrations are avoided. Finally, the concentration
of the targeting moiety can be modulated by varying the composition
of functional groups available for conjugation in the protocell lipid bilayer.
Given these considerations, selective targeting by functionalized proto-
cells can successfully circumvent binding site inhibition.
Below, we will discuss in detail the advantages of the protocell over
other types of nanocarriers. In a similar fashion, a variety of payload
cargos or payload combinations will be discussed including non-
invasive imaging agents and/or therapeutics, alone or in combination
depending on the application. Thus, we envision the modular design
of functionalized protocells may be tailored for a particular tumor type
or tumor subtype whose therapeutic payload can be personalized to ac-
commodate a prescribed clinical treatment plan. The objective of this
review is to 1) describe how targeting peptides and scFvs are select-
ed using in vivo and in vitro phage or antibody display and examine
their clinical utility, 2) compare a variety of simple and complex
nanocarriers and types of therapeutic cargos and 3) review various
conjugation strategies to functionalize nanocarriers and optimize thera-
peutic efﬁcacy. Ultimately, optimization and personalization of
Table 1
Peptide ligand motifs and corresponding tumor receptors.
Peptide ligand motif Tumor receptor In vitro In vivo Reference
RGD-4C, VVISYSMPD αvβ3 & αvβ5 Y Y [9,340]
TAASGVRSMH, LTLRWVGLMS NG2 Y Y [341]
CTTHWGFTLC MMP-2, MMP-9 Y Y [342]
NGR APN (CD13) Y Y [74–76,168,172]
RPL, CTQYAMHLC, CSQYSFNWC, CGFYWLRSC VEGFR-1, Neuropilin-1 Y Y [78,80,88,343–345]
CGRRAGGSC IL-11Rα Y Y [23,40–42]
CNVSDKSC (peptide epitope), WIFPWIQL, WDLAWMFRLPVG, SNTRVAP GRP78 Y Y [43,45,46,101]
CPRECESIC APA Y Y [84]
CKGGRAKDC Prohibitin (receptor identiﬁed in normal adipose tissue) Y Y [19,346,347]
CVPELGHEC HSP90 Y N [348]
GFE MDP (metastasis) Y Y [349]
CVRAC EGFR Y N [77]
WXDDG TWEAK Y N [350]
CLFMRLAWC, HDERMFLCKS MUC18 Y Y [351]
YRCTLNSPFFWEDMTHECHA CRKL Y Y [86]
CRTIGPSVC Transferrin Y Y [28]
GNFRYLAPP DNA-PKcs Y N [352]
CWKLGGGPC Human leukocyte proteinase-3 Y N [27]
CSGIGSGGC, CRFESSGGC EphA5 Y Y [18,29]
GLTFKSL PPP2R1A Y Y [83]
CTFAGSSC Fetuin-A Y N [85]
HSYWLRS, YKHSHSYWLRSGGGC NPTX2/NPTXR Y N [353]
YKWYYRGAA-pen RPL29 Y N [354]
CGIYRLRSC α6 integrin & E-cadherin complex Y N [355]
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be empirically determined.
2. Targeting strategies
2.1. Peptide phage display
In vitro phage display was originally reported as a novel method to
clone genes by using a known antibody to probe phage clones that dis-
play peptide epitopes as a fusion protein of the pIII minor coat protein
[58]. These studies showed that the correct peptide epitope was
enriched a thousand-fold after a single selection round. Since this initial
study, phage display of random peptide libraries displayed on pIII has
been used as an unbiased in vivo screening tool [59,60] to identify nu-
merous ligand-receptor pairs within the physiological context of nor-
mal brain, kidney, adipose tissue, lung, skin, pancreas, retina, intestine,
uterus, prostate, and adrenal glands [24,61,62] and in disease tissues,
both in humans and animal models [19,27,40,61,63–66]. Moreover,
in vivo phage display combined with ﬂuorescence laser pressure cata-
pult microdissection revealed endothelial receptors are differentially
expressed within specialized sub-cellular regions, such as pancreatic
islets, and are overexpressed in pancreatic islet tumors [67]. These re-
sults demonstrate receptors expressed by the vascular endothelia of
normal or disease tissues have an inherent and distinctive molecular
heterogeneity. This highlights the limitations of other methods to iden-
tify clinically relevant cell surface receptors by systematically proﬁling
protein expression, as they do not take anatomical context into account
despite the fact that some clinically important endothelial proteins are
expressed in restricted locations or become accessible only under spe-
ciﬁc biologic, physiologically- or pathologically-induced, circumstances.
2.1.1. Selecting peptides by in vivo phage display
In a typical in vivophage display experiment, a linear or circular pep-
tide librarywith up to 109 diversity, expressed on the bacteriophage pIII
minor coat protein, is injected intravenously so that circulating ligands
can preferentially bind to physiologically accessible cell surface recep-
tors (Fig. 1). The organ or tissue of interest is subsequently removed
after a period of time and tissue-speciﬁc bound phage are recovered
by bacterial infection so that the peptide coding sequences can be iden-
tiﬁed by DNA sequencing [40]. Alternatively, recovered phage frommultiple tissues of interest are tagged using PCR-assisted bar-coding
followed by high-throughput DNA sequencing [12,20,27].
After several iterative rounds of selection, peptide ligands are
enriched in the tissue of interest, since each successive round selects
for phage recovered from internalized, bound receptors. Bioinformatic
analyses of recovered peptide sequences in the forward and reverse
directions [68,69] reveals enriched tripeptide motifs, which deﬁne spe-
ciﬁc protein–protein interactions [70,71]. Enriched peptide sequences
or consensus sequences are cross-referenced against the NIH National
Center for Biotechnology Information (NCBI) protein database using
the Basic Local Alignment Search Tool (BLAST) to search for putative
protein “ligand” identities which in turnmay identify their correspond-
ing receptor. Candidate ligand:receptor pairs are veriﬁed using in vitro
phage binding assays and by ELISA if the putative receptor and appro-
priate antibodies are commercially available. Binding of individual
phage displaying a single peptide ligand is validated in vivo and novel
receptor proteins are subsequently isolated by afﬁnity chromatography
using puriﬁed, synthetic peptide ligands [72].
Thus far, we showed that screening libraries of phage-displayed
peptides by intravenous injection into mice, rats, swine, non-human
primates or brain-dead patients selects for peptides that bind speciﬁcal-
ly to normal or diseased organs/injured tissues. Importantly, and unlike
untargeted nanocarriers whose fate is affected by serum proteins [8],
synthetic peptides bind to the same receptors in these tissues as pep-
tides displayed on phage particles. Moreover, peptides displayed on
phage are capable of binding to post-translationally modiﬁed receptors
that are expressed on cell surfaces as molecular signatures intrinsic to
the microenvironment [73–76]. Not only do peptide-displaying phage
bind to physiologically accessible receptors, successive rounds of selection
enriches for peptides that bind to cell-surface receptors and are internal-
ized. Enrichment of phage in the target tissue increases from 3 to 35 fold
compared to untargeted, control phage [60]. Since 1998, considerable
progress has been made in the delivery of targeted peptidomimetic
drugs or imaging agents by our group and others as well as the isolation
of novel peptide ligands by improvements of in vivo phage display tech-
nology and bioinformatic analyses [9,12,17,18,20,27–29,43,63,77–82]. In-
deed, tissue-speciﬁc and angiogenesis-related vascular ligand-receptor
pairs have been identiﬁed and exploited for targeted delivery of cytotoxic
drugs, proapoptotic peptides, ﬂuorophores or cytokines to tumors, which
generally improves selectivity and/or therapeutic windows in preclinical
animal models.
Fig. 1. Drug development pipeline for BMTP-11. Development of a peptide-based therapeutic, BMTP-11, starting from in vivo phage display using a peptide combinatorial library in a
terminal wean patient identiﬁed a prostate tumor-speciﬁc peptide ligand, which led to receptor identiﬁcation and validation. Drug development of BMTP-11 included toxicological
studies in mice and cynomolgus monkeys followed by a ﬁrst-in-man phase 0 clinical trial, in which BMTP-11 localized and induced apoptosis of tumor cells at a secondary metastatic
site [23].
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The application of in vivo phage display technology is particularly
suitable for identifying and exploiting unique vascular receptors in
human diseases such as cancer, where tumor cell growth and prolifera-
tion arehighly dependent upon robust tumor bloodvessel growthdespite
their abnormal molecular signatures and structural morphologies. Due to
the leakiness of tumor blood vessels, in vivo phage display has identiﬁed
unique receptors expressed on tumor endothelial cells as well as on re-
ceptors expressed on stromal cells, the extracellular matrix, pericytes,
lymphatic endothelial cells and tumor cells [29,41,42,44,45,59,76,79,
83–85].Moreover, angiogenic blood vessels acquire uniquemolecular sig-
natures that can be exploited for speciﬁc, targeted delivery of therapeutic
agents [9,19,22,23,28,42,43,45,86,87]. Receptors on cultured tumor cells
have also been identiﬁed using a modiﬁed in vitro phage display tech-
nique called BRASIL in which phage bound to receptors expressed on
the surfaces of cultured cells are separated from unbound phage by cen-
trifugation from a miscible organic phase into an aqueous phase [18,88].
Analyses of peptide ligands recovered by the BRASIL method identiﬁed
EphA5 as a putative receptor expressed on the surface of cultured
human non-small lung tumor cells [18,89]. EphA5 expression was subse-
quently veriﬁed as a physiologically accessible, overexpressed receptor in
human lung cancer, and its expression correlates with radioinsensitivity.
Treatment of lung cancer cells or human lung xenografts with an EphA5
monoclonal antibody (mAb) improved tumor sensitivity to irradiation
and prolonged survival in tumor-bearing mice [29].
Phage display in a brain-dead human cancer patient revealed that
peptide motifs localize non-randomly to different organs [40,66]. One
selected peptide motif, GRRAGGS, was identiﬁed from a prostate biopsy
sample that exhibited sequence homology to interleukin 11 (IL-11). Our
group as well as others conﬁrmed IL-11 binds to its cognate receptor,
IL-11Rα [41,90,91], which is overexpressed during tumor progression
andmetastases in a large cohort of prostate cancer patients [42]. Similar
to prostate cancer, expression of IL-11 and IL-11Rα are signiﬁcantly
higher in breast cancer samples compared to healthy mammary tissue
[92]. Moreover, IL-11 and IL-11Rα transcript levels are approximately
3-fold greater in node-positive tumor samples compared to node-
negative tumor samples [92], indicating that their expression directly
correlates with the clinical and pathologic progression of breast cancer.
Taken together, the vascular accessibility of overexpressed IL-11Rα and
its role in human prostate and breast cancermake it a clinically relevant
therapeutic target.
Our studies with IL-11α expression in prostate cancer led to
the design of a ligand-directed agent, Bone Metastasis Targeting
Petidomimetic-11 (BMTP-11), which consists of the IL-11Rα bind-
ing peptide motif, CGRRAGGSC (Table 1), conjugated to the apopto-
tic peptide, D(KLAKLAK)2. D(KLAKLAK)2 is non-immunogenic and
nontoxic outside cells but disrupts mitochondrial membranes
when internalized [93,94]. We validated the efﬁcacy of BMTP-11 in
pre-clinical models of prostate cancer, and in murine and humanosteosarcomas [95]. Mice bearing DU-145, LNCaP prostate tumors or
implanted with a patient-derived MDA-PCa-118b tumor, an osteoblastic,
androgen receptor-independent prostate tumor [96], and treated with
BMTP-11 had signiﬁcantly smaller tumors compared to tumor-bearing
control mice treated with untargeted D(KLAKLAK)2 [23]. Toxicology
studies of BMTP-11 in cynomolgusmonkeys showed good stability, linear
accumulation over time and predictable metabolism [23]. A phase zero
clinical trial testing BMTP-11 as an investigational new drug in castrate-
resistant prostate cancer patients indicated that BMTP-11 induced
apoptosis of secondary bone metastasis. These results illustrate
how the IL-11Rα targeting peptide discovered by in vivo phage display
in a human subject was translated into a tumor-speciﬁc, clinically rele-
vant drug [23] (Fig. 1).
Unlike IL-11Rα expression in tumors, the identiﬁcation and valida-
tion of GRP78 (reviewed in [44,97]), in breast and prostate tumors
wasmore circuitous due to its associationwith the unfolded protein re-
sponse [98–100]. In vitro phage display of circulating antibodies derived
from prostate cancer patients recovered a peptide epitope, CNVSDKSC,
which was identiﬁed to be GRP78 [46]. We and other groups showed
that WDLAWMFRLPVG, WIFPWIQL and SNTRVAP-displaying phage
(Table 1) bind speciﬁcally to GRP78 [43,45,101]. Expression of GRP78
in the endoplasmic reticulum (ER) or cell surface is induced by acidosis,
hypoxia and imbalanced glucose metabolism; its expression serves as a
sentinel of ER-related stress in various pathological conditions, includ-
ing cancer [102,103]. Anti-GRP78 antibodies were identiﬁed in serum
from prostate cancer patients by in vitro phage display [46], and retro-
spective immunohistochemistry (IHC) studies showed that GRP78 ex-
pression predicts recurrence in prostate cancer patients [104] and
poor survival in advanced breast cancer [102,105]. Silencing GRP78 ex-
pression restored cancer cell sensitivity to chemotherapeutic regimens
and established a functional role for GRP78 in cancer cell survival
[102,105]. GRP78 expression correlates with metastatic disease in in-
ﬂammatory breast cancer, revealing a potential therapeutic target for
a disease that currently lacks an effective treatment. mAbs against
GRP78 show promise in pre-clinical studies and in early stage clinical
trials, thus substantiating the development of anti-GRP78 based thera-
pies [44,106]. Similar to IL-11Rα, cell surface overexpression and the
role of GRP78 in human breast and prostate cancer make it an ideal
therapeutic target [45,47].
2.2. Antibody display
In 1986, the FDA and EMA approved the ﬁrst therapeutic antibody,
the CD3 OKT3 mAb, to prevent organ rejection in kidney transplants.
Since then, the clinical use of antibody products has grown steadily,
with 38 antibody-based biotherapeutics as of May 2015 and more ex-
pected to be approved by the end of 2015 [107]. Antibody-mediated
therapeutic interventions have been successful because of their high
speciﬁcity and because they share the same structural features and
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gating potential safety issues in drug development.
2.2.1. Current applications of tumor-targeting antibodies
Antibody based therapies exert anti-tumor effects through a wide
variety of mechanisms. Antibody binding to a cell surface receptor is
sufﬁcient to trigger antibody-dependent cell-mediated cytotoxicity
[108], the effective mechanism of action for rituximab, the anti-CD20
mAb used to treat non-Hodgkin's lymphoma [109]. Bevacizumab, an
anti-VEGFmAb used to treat breast, metastatic colon and rectal carcino-
ma, arrests tumor angiogenesis by sequestering soluble VEGF and
inhibiting its binding to VEGFR-2 [110]. Antibodies that target different
epitopes of the same molecule show a potentiated therapeutic effect.
For example, binding of trastuzumab and pertuzumab to different do-
mains of the receptor tyrosine kinase HER2 prevents its dimerization
and results in enhanced antitumor activity [111,112]. The development
of HER2 antibody-drug conjugates (ADC, reviewed in [113]) represents
a step towards personalizedmedicine. HER2 breast cancer patients who
eventually develop resistance to trastuzumab or pertuzumab, possibly
due to activation of compensatory mitogenic signaling pathways, can
now be treated with the ADC, trastuzumab-DM1, that exploits the
tumor-targeting capability of the HER2 mAb to deliver a microtubule-
depolymerizing agent (DM1)with improved efﬁcacy, pharmacokinetics
and reduced toxicity [114].
More recently, antibodies that engage and activate the host immune
system against melanoma cells have pioneered clinical immunotherapy
treatment. Antibodies activate the immune system by targeting the
T-cell surface receptors CTLA4 (ipilimumab) or PD-1 (nivolumab) and
blocking negative regulators of T-cell activation. Combining these sepa-
rate immunotherapies in a phase 1 trial of advanced stage disease result-
ed in tumor regression in some, but not all, patients [115]. The efﬁcacy of
antibody-based immune checkpoint therapy has been proven in a variety
of cancers [116]. Other antibody-based therapies involve conjugating cy-
tokines [117] or bacterial toxins [118] to an antibody component have
shown varying degrees of efﬁcacy in clinical trials.
In the following sections, we describe how antibodies that bind
to cancer-speciﬁc proteins are selected by screening naïve antibody
libraries. The design of new cancer therapeutics that utilize targeted an-
tibodies, validated in vivo, to deliver therapeutic cargos in nanocarriers
will be discussed, as well as exploiting synergistic combinations of
antibodies with their delivered cargos as possible strategies for clinical
applications.
2.2.2. Selecting targeting antibodies
In principle, antibodies can be produced from cultured cells [119],
and can be engineered [120] or selected [121,122] against any target
protein to regulate its downstream effect. Nevertheless, for decades
the hybridoma technique developed by Köhler and Milstein was the
only reliable method to produce mAbs from splenocytes isolated
from mice immunized with a target antigen. The murine origin of
these mAbs however, elicited an immunogenic response in humans
and made them unsuitable for therapeutic use. Recombinant anti-
body technology initially enabled progressive reduction of immunogenic-
ity by producing human/mouse chimeric antibodies by engrafting the
mouse-speciﬁc complementarity determining regions (CDR) onto a
human antibody backbone (see [123] for a comprehensive review).
Finally, generation of the genetically engineered Xenomouse [124]
allowed producing target-speciﬁc human antibodies following anti-
gen immunization.
Parallel paths to generate human antibodies were established
through a combination of recombinant antibody and in vitro display
technologies to select target-speciﬁc human recombinant mAbs
(rhAbs) using a high-throughput approach. The concept of rhAb display
selection is based on the exploration of large antibody-like diversity
spaces (libraries) to obtain target-speciﬁc binders. To achieve this, the
complexity of antibodies – amolecular complex of 4 polypeptide chains– is reduced to its essential target-binding regions such as the scFv
[125], Fab [126] or nanobodies (camelid single variable domains)
[127]. These variations of full-length rhAbs are fully capable of binding
to target antigens, and are therefore called “antibody-like binders”. All
types of antibody-like binders have been explored for antibody display
and selection, and can eventually be engineered into full-length immu-
noglobulin (Ig)-like molecules (reviewed in [128]).
One of the most challenging aspects in antibody display technology
is the creation of large, diverse antibody-like libraries so that ideally, vir-
tually any antibody-like binder against any given targetmolecule can be
found. As opposed to peptide libraries, where short random sequences
can be generated using degenerate oligonucleotides, antibody libraries
suffer from several structural constraints (chain complexity, intra-/
inter-chain disulﬁde bond formation, proper folding of domains and
hydrophobic surface interactions) [129], which makes the creation of
large, functional libraries a daunting task. Nonetheless, several success-
ful diverse antibody libraries have been produced from naïve human
repertoires [25,130,131], restricted human antibody scaffolds with
natural diversities [126,132] or by designing synthetic diversities [133].
In general, antibody libraries are created by cloning however, approaches
using site-speciﬁc recombination [134] facilitate the creation of larger li-
braries with less effort. Although phage display [135] and its variations
(reviewed in [10]) have been the most popular display platform for re-
combinant antibody libraries to date, ribosome [136] or yeast display
[137–139] have also been successfully used to select high-afﬁnity anti-
body binders against desired target proteins.
By combining in vitro antibody phage display and antibody yeast
display [13,14], a pool of hundreds to thousands of speciﬁc antibody
binders from a large naïve human library can be ﬁne-tuned to bind to
a protein of interest. In these studies, pre-selection of a naïve
antibody-like library on the desired protein using antibody phage display
is followed by antibody yeast display in which limiting amounts of the
protein in the 2nd selection phase enriches for high afﬁnity antibody-
like binders. We commonly have used in vitro antibody phage and yeast
display in successive selection rounds to identify antibody binders to a
tumor-speciﬁc receptor.
Once the pool of antibody-like binders is selected and enriched from
a library, choosing an antibody for tumor targeting presents yet another
challenge. Speciﬁcity is clearly the driving aspect, but factors such as
high tumor interstitial pressure, which inﬂuence the distribution
of the targeting antibody within the tumor need to be considered as
well. For instance, suboptimal concentrations of the targeting antibody
to some tumor regions may lead to ineffective treatment and instigate
a potential source of resistant, mutant tumor cell populations. We
have found that next generation sequencing can identify the best anti-
bodies in a selected pool, providing the selection step is appropriately
designed [140].
Afﬁnity and size play another important role in antibody-based
targeting strategies. Although tumor uptake of large molecules (full-
length antibodies, nanoparticles) is mostly inﬂuenced by the EPR effect
[7,141], retention of smaller molecules (peptides, scFvs, Fabs, alternative
binding scaffolds) at the tumor site is highly dependent on their binding
kinetics [142–146]. Tumor targeting can be achieved either by using
small antibody-like binders with very high afﬁnities (pM to low nM) or
large antibodies with relatively lower afﬁnities (high nM range) and
longer half-lives in the bloodstream. Multivalency (more than one anti-
gen binding site per antibody or antibody-like molecule) is another pa-
rameter that favors retention of antibody-like binders or antibodies in
tumors and increases their functional afﬁnity [147–149].
Antibody penetration refers to the homogeneous distribution of an-
tibodies within the tumor and is another key factor to consider in
selecting solid tumor targeting antibodies for clinical application. Fac-
tors that retard tumor penetration are high afﬁnity and internalization.
Fujimori and colleagues introduced the concept of “binding site barrier”
in which high afﬁnity antigen/antibody interactions reduce the amount
of free antibodies available to diffuse into the tumor interstitium, thus
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Additionally, Wittrup and colleagues extensively demonstrated that
fast internalization rates and catabolism retard antibody penetration
[150]. Despite these studies, internalization following receptor binding
has been successfully exploited for delivery of ADCs (reviewed in
Section 2.2.1). Furthermore, cell-internalizing antibodies exist for a
variety of tumors, and are selected to bind to speciﬁcally identiﬁed
antigens or, using an unbiased approach, to unknown cell surface
receptors by screening cancer cells with antibody display libraries
[151–153]. The evolution of recombinant antibody and display tech-
nologies enable the selection of antibody-like binders with desired
properties that can overcome the binding kinetics and distribution
hurdles described above.
2.2.3. Validation of antibody-like binders in vivo
Unlike in vivo peptide phage display, which has been used to screen
diverse peptide libraries in terminal wean patients or animal models
[19,24,27,40,67,76,84], in vivo antibody display has proven to be a
more challenging task. To date, only Shukla, Krag and coworkers have
shown some degree of success by injecting naïve antibody phage librar-
ies in cancer patients [21,26], although, the selected antibodies tend to
be patient speciﬁc. Nevertheless, antibody-like binders to receptor tar-
gets identiﬁed by in vivo peptide phage display can be isolated by
screening a naïve human scFv library using the puriﬁed receptorFig. 2. Comparison of simple vs. complex nanocarriers. Complex nanocarriers incorporate high
bilayer of the functionalized protocell may contain selective polymers, such as PEG (green) or ch
functional moieties for conjugating targeting peptides (red) or fusogenic peptides to promote e
increase drug concentrations at the tumor site and allow protocells to target different tumorsprotein. Unpublished data from our group indicate that a combination
of in vitro and in vivo antibody display yields tumor-speciﬁc antibodies
when recombinant tumor receptors (identiﬁed by in vivo or in vitropep-
tide phage display) are used as selection targets. In these studies, an
in vitro pre-selected, enriched antibody phage sub-library containing
antibody clones that speciﬁcally bind to a known, overexpressed cell
surface tumor-speciﬁc protein was injected into tumor-bearing mice.
Several tumor-localizing rhAbs were recovered from the tumor after
assessing their biodistribution using next generation sequencing [140,
154] and immunohistological analyses of tumor sections relative to con-
trol organs. Speciﬁc therapeutic characteristics such as receptor inhibi-
tion by direct or allosteric binding or conjugation to imaging dyes or
therapeutic drugs can be evaluated in vivo so that tumor-speciﬁc recep-
tors can be fully exploited for treatment by functionalized protocells.
3. Nanocarriers
The experimental design by which tumor-speciﬁc peptides and re-
combinant human scFvs are selected within the physiological setting
is a signiﬁcant improvement for targeted drug delivery. By using
tumor-targeting peptides, we and others have successfully demonstrat-
ed in vivo tumor growth inhibition using tumor-targeting peptides to
deliver: D(KLAKLAK)2 [23,94], doxorubicin to treat tumor-bearing
mice [9], TNF-α [11,15,16,22,30], and reporter or suicide genes [17,loading capacity of a variety of cargos, greater stability and high biocompatibility. The lipid
olesterol (purple diamonds) to improvemembrane ﬂuidity and overall charge. Additional
ndosomal escape (blue) may be added. These modiﬁcations optimize protocell retention,
[38].
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simple and complex nanocarriers will be examined including a discus-
sion of different types of therapeutic cargos.
3.1. Simple nanocarriers
Awide variety of nanoparticles have been developed for the delivery
of therapeutic cargos including magnetic and metallic nanoparticles,
such as iron oxide or gold nanoparticles, carbon based structures, such
as graphene sheets and carbon nanotubes, polymer nanoparticles,
dendrimers, quantumdots, hydrogel-baseddelivery systems, liposomes
and silica-based nanoparticles (Fig. 2). Each nanocarrier type has
strengths and weaknesses, which can be exploited for speciﬁc appli-
cations. For example, metallic nanoparticles act inherently as con-
trast agents for imaging while other nanocarriers would require
the addition of an imaging agent. The advantages and disadvantages
of nanocarriers for therapeutic delivery and repetitive dosing are
summarized in Table 2.
Magnetic-based nanoparticles, most commonly iron oxide nanopar-
ticles, have the theoretical advantage of precise therapeutic delivery to
the region of interest using a magnet [155–157]. Additionally, metallic
nanoparticles have the potential for multimodal, theranostic applications
[158–161]. The theranostic potential of magnetic iron oxide particles is
supported by FDA approval of a number of iron oxide nanoparticle imag-
ing agents [157,162]. The non-degradable nature ofmagnetic andmetallic
nanoparticles however limits repeated applications for therapeutic efﬁca-
cy due to their accumulation [156,163]. For example, iron based nanopar-
ticles degrade slowly in biological systems such that even a single dose of
iron oxide nanoparticles shows signiﬁcant accumulation in the liver,
spleen and lungs 90days post-injection [164], and eliminationof accumu-
lated iron through the urine and feces occurs slowly [157,165]. Finally, the
solidnature of themagnetic nanoparticle limits the amount of therapeutic
cargo that can be delivered. In addition to iron oxide nanoparticles, the
other most commonly proposed metallic therapeutic nanoparticle is
gold (Au).
Although Au nanoparticles have the potential to work as imaging
agents or in photothermal therapies, are biocompatible, and show no sig-
niﬁcant toxicity, they accumulate, typically for months post-injection,Table 2
Advantages and disadvantages of various nanocarrier platforms for therapeutic delivery.
Nanocarrier Advantages
Magnetic nanoparticles Magnetic targeting [155–157]
Imaging potential [158–161]
Previous FDA approval [157,162]
Control of size and shape [155]
Gold (Au) nanoparticles Highly biocompatible [157,163,166–1
Imaging potential [356]
Potential for photothermal therapy [1
Graphene sheets Very high loading capacity [159,171]
Stable in suspension [171]
Single-walled carbon nanotubes Very high loading capacity [159]
Low synthesis cost [157]
Multi-walled carbon nanotubes Very high loading capacity [159]
Low synthesis cost [157]
Mesoporous silica nanoparticles (MSNP) Biocompatible [189]
Biodegradable [178,188,190,191]
Very high loading capacity [176,183,1
Liposomes Biocompatible [33,198–201]
Ease of synthesis [33]
Flexible formulation [33]
FDA approved [195,197,198]
Potential to add targeting moieties [3
Polymeric nanoparticles Biocompatible [157,159]
Easy to manufacture [159]
High loading capacity [157]
Potential to add targeting moieties [2particularly in the liver and spleen [157,163,166–168]. Although the accu-
mulation of Aunanoparticles has not been associatedwith adverse effects,
their lack of biodegradation is of concern for development as therapeutic
delivery nanocarriers. Furthermore, the therapeutic loading potential of
Au nanoparticles is constrained by their solid structure thereby limiting
the therapeutic dose per particle.
To increase therapeutic loading, nanocarriers with very high loading
potential such as carbon and silica framework structures including
mesoporous silica nanoparticles (MSNP), carbon nanotubes and
graphene sheets have been explored. The primary interest in the
carbon-based structures is that their extremely large surface area
exposes every atom leading to the possibility of ultra-dense
functionalization and therapeutic loading [159]. Despite these ad-
vantages, the major disadvantage of carbon-based structures is
their limited biodegradability, which causes systemic buildup upon
repeated use and potential pulmonary and immune toxicity [159,
169–175]. Similar to carbon-based nanocarriers, MSNPs are charac-
terized by exceptionally high internal surface areas ranging from
500 to over 1200 m2/g due to periodic arrangements of uniformly
sized mesopores (ranging in diameter from 2 to N20 nm) embedded
within an amorphous silica framework [176]. Methods to synthesize
MSNPs allow for a variety of sizes ranging from 25 nm to over
250 nm, and the MSNP shape can vary from prismatic to spherical
to toroidal to rod-like [177–182]. Additionally, the MSNP pore diameter
can range from 2 nm to over 20 nm and, by using silane coupling
chemistry, the pore surface chemistry can be altered to accommodate
high concentrations of disparate cargos [183–186]. Anothermajor advan-
tage of MSNPs is that amorphous silica is Generally Recognized As Safe
(GRAS) by the FDAand recently, a silica-basednanoparticlewas approved
for diagnostic applications in a Phase I human clinical trial [187]. Although
amorphous silica is GRAS, biocompatibility testing ofMSNPshas beenvar-
iable. Occasionally, MSNPs test positive for toxicity, which is most likely
due to incomplete removal of residual surfactant used to template the
pores [188]. Conﬁrmed removal of the surfactant prior to toxicity testing
has shown that very large doses ofMSNPs do not adversely affect survival
in mice [189]. In addition to its low toxicity, the porous silica framework
ofMSNPs promotes a high rate of dissolution into soluble, non-toxic silicic
acid species that are easily cleared from tested in vivo systems [178,188,Disadvantages
No internal loading capacity [155]




No internal loading capacity
Poor biodegradation [157,163,166,167]
Dose dependent toxicity in vivo [171]
Non-biodegradable [171]
Potential for pulmonary injury in vivo [157,172]
Immune suppression [172]
Accumulation in organs [157,172,173]
Accumulation in organs [157,159,357]
Potential for pulmonary damage [157,175]
Immune suppression [157,174]
85,186]
Instability in physiological buffers [176]
Poor circulation, rapid clearance [178,192–194]
3,196,202,203]
Poor universal carrier [204,205]
Invariant size and shape [200,219,220]
Poorly controllable drug release characteristics [198–201]
13]
Limited in vivo stability [159,218]
Poorly controllable drug release characteristics [198–201]
Dose dependent toxicity [159,218]
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physiological buffers and rapid clearance by the mononuclear phagocyte
system (MPS) after injection [178,190,192–194], which can be mitigated
by coating or encapsulation with polymers or lipids vide infra.
To avoid bioaccumulation and uptake by theMPS, highly biocompat-
ible systems such as polymer and lipid based nanostructures have been
employed. One of the most successful nanoparticle formulations is a
liposomal nanoparticle-based drug delivery of which several FDA ap-
proved formulations exist [195–197]. The advantages of liposomes are
their high biocompatibility, ﬂexible formulation and easy synthesis
[33,198–201]. Moreover, liposomal formulations can be targeted specif-
ically to tumors by incorporating antibodies such as the GAH, anti-EGFR
or anti-HER2 mAbs, small molecules such as folate, transferrin or
tumor-targeting peptides such as cyclic RGD [33,196,202,203]. Unfortu-
nately, the success of liposomal formulations varieswith the encapsulated
drug. Stable lipid formulations of some common chemotherapeutics have
been difﬁcult to determine, in particular to limit drug leakage, making
liposomes a poor universal carrier [204,205]. Nevertheless, liposomal en-
capsulation signiﬁcantly reduces toxic off-target effects while retaining
clinical efﬁcacy for chemotherapeutics such as doxorubicin [206–209],
cisplatin [210], camptothecin [211], irinotecan and ﬂoxuridine [212].
Polymeric based nanocarriers have also been developed and several
novel formulations are currently undergoing clinical trials [196]. In one
example, the small cell lung cancer targeting peptide, AHSGMYP, was
used to deliver docetaxel loaded into a polylactic acid polymer nano-
carrier [213]. Treatment of nude mice bearing small cell lung cancer tu-
mors with AHSGMYP-conjugated docetaxel nanoparticles resulted in
higher tumor docetaxel accumulation and survival compared to tumor-
bearingmice treatedwith untargeted docetaxel nanoparticles. Antibodies
have also been used to target liposomal drugs [214–216], an approach
that requires the addition of lipid tails to the C-terminus of the antibody
[215,217] in order to incorporate into liposomes.
Similar to lipid formulations, many polymer-based nanoparticles are
highly biocompatible and easy to produce however, they also suffer
from limited stability in in vivo systems and dose-dependent toxicity
[159,218]. Furthermore, both liposomes and polymer-based nanocarriers
are subject to invariant size and shape, poorly controllable release proﬁles
and highly interdependent factors whereby altering one parameter, such
as size, affects loading efﬁciency, charge and stability [200,219,220].
3.2. Complex nanocarriers
To address the speciﬁc limitations described above, complex nano-
carriers combine multiple features of simple nanocarriers to exploit
their strengths, as well as reduce or eliminate their limitations [37,38,
194,221–231] (Fig. 2). For example, both liposomes and polymer-based
nanoparticles have good circulation half-lives and biocompatibility but
limited stability and drug retention. These limitations can be improved
by the inclusion of a stable nanoparticle core within polymeric or liposo-
mal carriers. The combination of polymers or lipids with a stable core can
be accomplished with magnetic nanoparticles, Au nanoparticles, carbon-
based nanocarriers and MSNPs. For example, polygalacturonic acid was
used to coat magnetic cobalt spinel ferrite nanoparticles and then conju-
gated to an EphA2 binding peptide. The resultant complex nanocarrier
was used to extract metastatic ovarian cancer cells from the abdominal
cavity and circulation [232]. For delivery of therapeutic cargos, the nano-
particle core should have good biocompatibility and biodegradation to
allow repeated dosing, a high surface area for high therapeutic loading
and a tunable nature to permit loading with a variety of cargos. As de-
scribed above, MSNPs are biodegradable, biocompatible, stable and po-
rous. Moreover, their facile chemistry allows them to act as a tunable
base to load a variety of cargos, as well as a number of covalent and
non-covalent coatings. The simple addition of a polymer to the surface
of MSNPs, such as polyethylene glycol (PEG), PEG-polyethylenimine
(PEI) or poly(N-isopropylacrylamide-co-methacrylic acid) (NIPAM-co-
MAA), greatly increases their circulation time and allows signiﬁcantaccumulation in tumors by utilizing the EPR effect [233,234] and
demonstrates signiﬁcant delivery of therapeutic drugs in preclinical
in vivo models of cancer [233–236]. In addition to polymers, their
facile chemistry allows the addition of targeting agents, such as
transferrin or folic acid, to their surface [189,190,237,238]. Polymer-
coated and targeted MSNPs are currently being used to reassess chemo-
therapeutics such as selenocystine, whose clinical efﬁcacy was previously
hindered by low selectivity, solubility and stability [189].
Increased ﬂexibility and versatility were achieved by combining
liposomes and MSNPs to create a “protocell” [37–39,176,224,239].
Protocells are formed by the encapsulation of the MSNP core within a
supported lipid bilayer (SLB), followed by the optional conjugation of
polymers, such as PEG, and targeting or trafﬁcking ligands to the surface
of the SLB [37,38,177,194,222,224,240–245]. Protocells synergistically
combine the advantages of liposomes, low inherent toxicity and immu-
nogenicity, and long circulation times, with the advantages of MSNPs,
stability and enormous capacity for multiple cargos and disparate
cargo combinations [38,176]. The adhesion energy between the MSNP
and the lipid layer suppresses large-scale membrane bilayer ﬂuctua-
tions, resulting in reduced liposome instability and leakage, and the
lipid bilayer permits retention of soluble cargos. Since its inception,
the facile chemistry of theMSNP and variability of lipid bilayer formula-
tions have led to a wide variety of protocell designs to include: lipid
monolayer encapsulated hydrophobic MSNPs to load hydrophobic
cargos [194,240], covalent attachment of lipids to enable triggered
cargo release [246], polymer additives to the lipid layer to enhance cir-
culation times and the EPR effect [240,245], and native cell membrane
encapsulated particles to improve biocompatibility [240,247] including
lipid compositions that mimic red blood cells [246].
3.3. Therapeutic payloads
3.3.1. Imaging agents
The highly modiﬁable nature and large cargo capacity of MSNPs
enables the inclusion of an imaging modality with therapeutics. For ex-
ample, inclusion of a near infrared (NIR) [242] or ﬂuorescent dyes such
as ﬂuorescein isothiocyanate (FITC) [190] in MSNPs permits imaging
in vivo for real timebiodistribution analyses of novel nanocarriers after in-
travenous injection. Labeling MSNPs with NIR dyes enabled the analysis
of their biodistribution over time, and the evaluation of various surface
coatings such as PEG or PEG-PEI on their biodistribution and clearance
in vivo [234]. Inclusion of ﬂuorescent dyes provides the added
advantage of visualizing MSNP localization in tissues after animal dissec-
tion to conﬁrmMSNP biodistribution studies [190,248,249]. Other encap-
sulated visualization agents include radioactive nuclides for positron
emission tomography (PET) [248] or superparamagnetic iron oxide
particles as an MRI contrast agent [250–252]. The structure and fac-
ile chemistry of the MSNP platform even allows multiple labels to be
incorporated into the same particle, thereby enabling simultaneous
conﬁrmation of nanoparticle biodistribution in real time [251]. A simi-
lar approach [253] has been proposed to identify patients who may ben-
eﬁt fromantibody targeted liposomes,whereby tumors areﬁrst tested for
their ability to internalize ﬂuorescent liposomes displaying speciﬁc anti-
bodies. If internalized ﬂuorescence is noted, liposomes bearing cytotoxic
payloads will be similarly internalized, and consequently therapeutic.
In addition to their use in research,MSNPs have a potential beneﬁt in
the clinical setting as imaging agents. The ability to readily incorporate
imaging agents such as NIR dyes or radioligands makes them ideal for
image-guided removal of sentinel lymph nodes or small metastatic
foci [254]. This approach was demonstrated using the Cornell dot or
“C dot”, which was recently used in a melanoma ﬁrst-in-human trial
[187]. The C dot is an ultra small, 6–7 nm, silica nanoparticle containing
Cy5 ﬂuorescent molecules in the core particle, coated with PEG and
furthermodiﬁedwith radioactive iodine for PET and the cRGDY peptide
for integrin-mediated targeting [255]. The dual functionality of C dots
facilitated whole body PET imaging and ﬂuorescence optical imaging
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can be targeted using tumor-speciﬁc peptides or antibody-like binders,
can contain imaging agents, radioligands or therapeutic agents, and
can be easily coated with polymers or engineered into functionalized
protocells to create biocompatible, targeted imaging agents and/or
theranostics [37,38].3.3.2. Chemotoxins
The most common area of research for therapeutic MSNPs is che-
motherapeutic delivery. Although most studies have focused on sys-
temic delivery, an inhalation delivery study reported signiﬁcant
localization of a luteinizing hormone-releasing hormone peptide
targeted-MSNP in a model of lung cancer compared to intravenous
administration [257]. These studies demonstrated that localized de-
livery might be advantageous depending on the location of the
tumor.
Many current studies involving systemic delivery of therapeutic
MSNPs to tumors have focused on taking advantage of the EPR effect.
For example, even bare uncoated MSNPs show therapeutic advantages
over free drug in tumor xenografts [190]. Surface modiﬁcation of
MSNPs with PEG, or PEG-PEI enhanced EPR-based accumulation in tu-
mors and resulted in increased drug efﬁcacy and reduced toxicity
[234,235,258]. In a similar fashion, modiﬁcations of protocell constructs
have also been utilized to enhance drug delivery via the EPR effect [242,
244,245]. The addition of the lipid bilayer allows delivery of a hydrophil-
ic drug within the MSNP core and a hydrophobic drug within the lipid
bilayer [242]. Polymers associated with the protocell can also exert a
therapeutic effect. For instance, the inclusion of Pluronic 123 blocks
the action of the breast cancer resistance protein pump and increases
the efﬁcacy of the chemotherapeutic cargo in a xenograft breast cancer
model [245].
Although the EPR effect can be used bymodiﬁed nanocarriers to im-
prove drug delivery, recent studies indicate a trend towards adding
tumor-targeting moieties to MSNP surfaces [190,237,238,244,257].
Tumor targeting ensured delivery for tumor types and in patients
for which the EPR effect is insufﬁcient for treatment [259,260]. When
directly compared to non-targetedMSNPs, targetedMSNPs showed en-
hanced therapeutic efﬁcacy and decreased toxicity over non-targeted
MSNPs [189,190,237,238]. For example, the addition of the targeting
moiety hyaluronan to protocells enhanced their delivery of docetaxel
to a xenograft breast cancer model [244].
The use of polymer coated MSNPs has even been explored to treat
non-cancer cells to improve vascular access of drugs in difﬁcult cancer
types such as pancreatic ductal adenocarcinoma (PDAC). PDAC elicits
a dense stromal response that limits vascular access due to pericyte
coverage of vascular fenestrations and is a contributing factor to
chemotherapy resistance. Tumor-bearing mice treated with an ini-
tial delivery of MSNPs containing the TGF-β inhibitor, LY364947,
to decrease vascular pericyte coverage, followed by treatment with
liposomes containing gemcitabine showed reduced tumor burden
compared to treatment with free drug or gemcitabine-loaded lipo-
somes only [236].
Thus, MSNPs show promise for delivering a wide variety of che-
motherapy agents with decreased toxicity [233,235,238,244,245],
and may resurrect shelved drugs such as selenocystine [189],
whose clinical use has been hindered by low stability or solubility.
MSNPs also provide the capability for combinations of therapy
agents to be delivered either individually [244] or within a single
nanocarrier [242,258]. New functionalities, such as pH-responsive
nanovalves on multifunctional transferrin-modiﬁed MSNPs loaded
with ﬂuorescent molecules show effective cargo release in vitro and
in vivo [237]. These technological advances show the versatility and
tunablity of MSNPs in biological systems that capitalize their high
loading capacities to ensure targeted, high chemotoxin therapeutic
indices at the tumor site.3.3.3. Reporter and/or suicide genes
Gene delivery to cells in biological systems has been explored using
both viral and non-viral vectors. Despite its potential beneﬁt, gene
therapy is limited since modiﬁed adenoviral vectors may elicit an im-
mune response and cell transduction may be inefﬁcient. To construct a
targeted adenoviral vector, we introduced an adeno-associated virus
(AAV) bacteriophage chimeric vector termed AAVP [17]. We used the
RGD-4Cpeptide (Table 1) to target AAVP containing theHerpes simplex
virus thymidine kinase gene (HSVtk) to humanDU-145 prostate tumors
in tumor-bearing mice. The RGD-4C AAVP-HSVtk vector successfully
transduced tumor cells since expressed thymidine kinase enabled
tumor imaging by PET in the presence of the substrate [18F]-FEAU.
Moreover, tumor growthwas inhibited in the presence of the thymidine
kinase substrate, ganciclovir, compared to tumor-bearing mice treated
with untargeted AAVP-HSVtk.
By utilizing aMSNP carrier, plasmidDNA is protected from enzymat-
ic degradation in thebiological environment [261,262], facilitating entry
of plasmid DNA into cells. In vitro delivery of green ﬂuorescent protein
(gfp) reporter plasmids and therapeutic plasmids by polymer-coated
MSNPs has been reported [263–268]. Modifying nanocarriers contain-
ing genetic material with tumor-targeted peptides or scFvs that are in-
ternalized upon binding improves speciﬁcity and safety by ensuring
only targeted cells will be transduced.
3.3.4. siRNA
Small interfering RNAs (siRNAs) can be targeted to any number of
currently undruggable genes and, for instance, to ampliﬁed genes in
cancer [159,269]. Given the potential for siRNA to arrest growth of a va-
riety of tumors [270,271], a number of clinical trials are currently under-
way which utilize siRNA technology [159,272]. Unprotected, naked
siRNAs are subject to rapid degradation, on the order of 5min, in the ex-
tracellular environment and can also lead to systemic inﬂammation,
making the use of a carrier vehicle essential for effective siRNA delivery
[159,269,272].
A variety of nanocarriers including MSNPs have been utilized to de-
liver siRNA in vitro and in vivo [159,218,273,274]. The earliest studies
utilized theMSNP surface and a protective polymer coating to encapsu-
late and protect siRNA [268,275–277]. Surface association limited the
amount of siRNA that could be delivered to a level similar to other
solid nanocarriers, and the porous MSNP structure could be ﬁlled with
other therapeutics for dual delivery. Later studies focused on loading
siRNA into the MSNP pore structure to facilitate greater loading [278].
Therapeutic delivery of siRNA utilizing MSNPs with polymer coatings
has been demonstrated in a variety of in vivo cancer models [250,258,
279–283]. Co-delivery of therapeutic drugs with siRNA within a single
MSNP has been shown both in vitro [277] and in vivo [258]. While the
majority of the studies to date have utilized the EPR effect to deliver
siRNA to the tumors, targeted delivery has also been demonstrated
in vitro [37,277] and in vivo [282].We recently reported PCA3, a prostate
cancer biomarker, is an antisense intronic long noncoding RNA that reg-
ulates PRUNE2 levels via a unique regulatory mechanism by forming a
PRUNE2/PCA3 double-stranded RNA that undergoes RNA editing
[271]. These results established PCA3 as a dominant-negative onco-
gene and PRUNE2 as an unrecognized tumor suppressor in human
prostate cancer. LNCaP prostate tumor-bearing mice treated with a
stabilized anti-sense PCA3 siRNA resulted in signiﬁcant tumor
growth inhibition and concomitant decreased serum PSA concentra-
tions compared to tumor-bearing mice injected with a scrambled
siRNA control. These studies show that siRNA against PCA3 repre-
sents a promising effective nanocarrier cargo to inhibit PCA3 activity
and effectively manage prostate tumor growth.
Nanocarrier cargos can become entrapped in the endosome, and
endosomal escape is particularly important for nucleic acid delivery.
Endosomal escape can be achieved by adding fusogenic lipids,
endosomal escape peptides, membrane disruptive polymers or
lysosomotropic agents to the surface of the nanocarrier or with the
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during cell transfection is attained by incorporating fusogenic lipids,
commonly cationic lipids, into liposomes. Other helper lipids, such
as dioleoylphosphatidylethanolamine, are often added to promote
fusion of liposomes to endosomal membranes and enhance nucleic
acid release into the cytosol [284]. Liposomes containing cationic
lipids have successfully delivered siRNA [286–289] and plasmid
DNA [290–292] both in vitro and in vivo. In addition to their use in
liposomes, fusogenic lipids can also be included into the lipid bilayer
of protocells [39,222,241].
3.3.5. Aptamers
Although the majority of aptamer research has focused on extracel-
lular targets, the interactions of aptamers with intracellular proteins
may prevent binding of a secondarymolecule or alter enzymatic activity
or gene expression and therefore, has potential for therapeutic applica-
tions. The use of targeted, internalized nanocarriers can transport
aptamers into cells and permit clinical development of intracellular
aptamers. Additionally, loading aptamerswithin nanocarriers would al-
leviate two other challenges, namely nuclease-mediated degradation
and rapid renal clearance [293,294]. Due to their small size, aptamers
are rapidly degraded with half-lives as fast as 10–15 min [293]. To re-
duce renal clearance rates, aptamers are currently conjugated to high
molecular weight molecules like PEG or cholesterol which increases
their half-lives to as long as 12–24 h [293]. Nevertheless, their protec-
tion within a nanocarrier would avoid conjugation to a secondary moi-
ety, which may potentially alter target binding.
RNA based aptamers have been developed that can bind to T-cell
factor 1, WT1 and β-catenin and alter their transcriptional activity in
colon cancer and Wilms' tumors [295–297]. RNA aptamer binding to
β-catenin inhibits the β-catenin dependent transcription of cyclin D1
and c-myc in colon cancer cells that results in cell cycle arrest and re-
duced tumor forming potential in colony formation assays [296]. DNA
based aptamers have also been designed to interact with transcription
factors, such as Ampliﬁed in Breast Cancer 1 which is a transcriptional
activator and oncogene that is over expressed in a number of human
cancers [298]. In addition to transcription factors, DNA based aptamers
have been designed to functionally bind to the eIF4e eukaryotic transla-
tion initiation factor. Transfection of HeLa and HEK293 cells with eIF4e
aptamers reduced cell proliferation that was concentration-dependent
[299]. Non-faithful recombination by BCR-ABL1-mediated tyrosine
phosphorylation of RAD51 at residue 315 (pY315) may play an impor-
tant role in the accumulation of chromosomal aberrations and lead
to chronic myelogenous leukemia relapse and progression. Peptide
aptamers were developed to act as a decoy for RAD51(pY315), and
treatment of BCR-ABL1–32Dcl3 cells inhibited non-faithful homologous
recombination by approximately 2-fold [300]. Peptide aptamers have
also been designed to modify the activity of heat shock proteins 27
(HSP27) and 70 (HSP70) [301,302]. Over-expression of HSP27 and
HSP70 has been associated with chemotherapy insensitivity and de-
creased tumor cell apoptosis. Treatment of mice bearing B16F10 subcu-
taneous melanoma with peptide aptamers increased chemosensitivity
and reduced tumor burden in vivo [301].
4. Conjugation strategies to functionalize nanocarriers
As discussed above, the efﬁcacy of innovative nanocarriers to treat
tumors can be signiﬁcantly improved by targeting. Conjugation strate-
gies that covalently or non-covalently link targeting moieties such as
peptides, scFvs or ﬂuorescent molecules to nanocarrier surfaces
are detailed in Fig. 3. The selection of an appropriate conjugation
strategy is not trivial since the function of the targeting moiety has
to be preserved and may be sensitive to alterations in secondary
structure integrity during the conjugation process. Other consider-
ations include proper orientation, and density per nanoparticle. As
detailed below, direct conjugation strategies utilize existing surfacefunctional groups and a single step process, whereas multi-step
conjugation strategies employ the addition of a new chemical entity
to attach targeting moieties to functional groups on nanocarriers
[303,304].
4.1. Direct chemical conjugation strategies
4.1.1. Basic conjugation chemistries
Direct conjugation of a targeting moiety or an imaging agent to a
nanocarrier may require the addition of functional groups to the
surface of the nanocarrier. Surface functional groups on MSNPs can
be added by co-condensation during nanoparticle preparation or
by post-modiﬁcation of surface silanols after nanoparticle preparation.
This same strategy can be employed for conjugation of targetingmoieties
to complex nanocarriers such as protocells. Speciﬁc lipid compositions
can be selected or synthesized to allow direct conjugation of targeting
moieties onto liposome or protocell surfaces [305]. For example, amine
groups present on the MNSP surface, added either during synthesis or
as a post-modiﬁcation, have high reactivity with isothiocyanates and are
used to attach ﬂuorescent probes, such as FITC or rhodamine isothiocya-
nate (RITC), [306]. Adding thiol functional groups, can also be used to con-
jugate targeting moieties. A thiol group on the nanocarrier surface can be
conjugated to a second thiol grouppresent in the targetingmoiety to form
a disulﬁde bond.
Although this reaction is fast and efﬁcient, the disulﬁde bond is un-
stable over time under physiological conditions [307]. Nevertheless, a
disulﬁde bond was used to conjugate anti-My9 mAbs onto stealth lipo-
somes containing the cationic ionophore monesin. These antibody-
liposomes conjugates bound to CD33 expressed on human HL-60
promyelocytic leukemia cells and potentiated the in vitro cytotoxicity
of the anti-My9 immunotoxin by a factor of 2070 [308]. The reduction
of cysteine residues is a commonmethod used to conjugate thiol groups
on biomolecules with maleimide functional groups on nanocarrier
surfaces. These reactions are selective, produce good yields and are
stable in human serum for over a day even in the presence of a re-
ducing agent. This type of conjugation strategy has been intensively
explored to link anti-HER2 mAbs to liposomes for breast cancer
therapy [309–311].
4.1.2. Click chemistry
In the last decade, the emergence of click chemistry introduced a
new set of reactions to conjugate targeting moieties to nanoparticles
(reviewed in [312] for liposome conjugation). These new reactions are
particularly popular because they are highly speciﬁc, efﬁcient, physio-
logically stable, generate a single reaction product, produce high yields
and can be performed under mild reaction conditions in aqueous
solutions. Moreover, unreacted functional groups do not result in non-
speciﬁc binding compared to the amine or thiol group linkages detailed
above. Three major classes of reactions are employed: Copper catalyzed
Azide–Alkyne Click Chemistry (CuAAC) which involves the reaction be-
tween an azide and an alkyne under Cu(I) [313], Strain-promoted
Azide–Alkyne Click Chemistry reaction (SPAAC), commonly called Cop-
per free click chemistry, which involves the same components butwith-
out a catalyst [314], and Tetrazine-trans-Cyclooctene (TCO) ligation
[315].
4.1.3. Histidine tag
The nitrilotriacetic acid (NTA)/Ni2+ complex was ﬁrst used to afﬁn-
ity purify proteins containing a polyhistidine tag (His-Tag) of 6 histidine
residues, and can comprise up to 14 residues, at either the N or C termi-
nus with 100 fM afﬁnity. Subsequently, the NTA/Ni2+ complex was
used to link His6-Tag-biomolecules to nanocarriers since their dissocia-
tion constant is stronger thanmost antibody interactions [316] without
non-speciﬁc binding [317]. In 1999, Hainfeld et al. presented one of the
ﬁrst applications of His6-Tag on gold nanoparticles in which the NTA/
Fig. 3. Covalent and non-covalent conjugation strategies for nanocarriers. (A) Schematic representation of conjugating targeting moieties to resident functional groups (red or gray
spheres) on the phospholipid head groups of the protocell outer lipid leaﬂet using a one- or two-step process. (B) Common single-step conjugation strategies include covalent
traditional conjugation strategies, click chemistry, NTA/Ni2+-His6 or hydrophobic coiled/coil interactions. (C) Linking targeting moieties that contain sulfhydryl groups utilize a two-
step reaction that require homo- or hetero-bifunctional crosslinkers or clickable linkers.
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to reaction with a His6-tagged protein [318].4.1.4. Coiled/coil
α-helical coiled-coil interactions are naturally occurring tertiary
structures in awide variety of proteins, whereby oligomerization events
are energetically favored and are key tomany biological functions [319].
The typical primary structure is based on the (a–b–c–d–e–f–g)n repeat-
ed amino acid motif, where positions a and d are typically occupied by
hydrophobic residues thatmediate coil oligomerization,while positions
e and gmediate interhelical electrostatic interactions.Inspired by nature, a variety of coiled-coil pairs were designed
and exploited as biosensors, and as protein expression and puriﬁca-
tion tags. The E and K heterodimer coil pair [320] and its variants
[321] are two parallel coils composed of 5 repeats of 7 amino acids.
Their interaction afﬁnity is as low as 60 pM and they have been suc-
cessfully used in a variety of applications, including ﬂow cytometry-
based high-throughput screens [322] to display GFP and its variants
on phage particles [323]. Due to the stability, strength and speciﬁcity
of the coiled/coil interaction, we envision the use of E/K coils as a
straightforward and versatile conjugation strategy to functionalize
protocells. In the proposed protocell design, the protocell is func-
tionalized through its association with the K-coil and the targeting
278 V.J. Yao et al. / Journal of Controlled Release 240 (2016) 267–286moiety is expressed, chemically linked or synthesized as a fusion
protein product containing the E-coil.
4.2. Multi-step conjugation strategies
4.2.1. Avidin, neutrAvidin and streptavidin
The avidin–biotin complex is one of the oldest crosslinker conjuga-
tion techniques [324] and also represents one of the strongest non-
covalent bonds, with a Kd ~ 10−15 M. The highly speciﬁc interaction
between avidin and biotin is utilized to decorate avidin-containing lipo-
someswith biotinylated antibodies. Othermodels have been developed
based on the avidin/biotin complex [325] such as streptavidin and
neutrAvidin. The characteristics of these proteins include lower molec-
ular weight and the absence of carbohydrates, which decreases isoelec-
tric points and in turn, non-speciﬁc binding. Although the avidin–biotin
conjugation techniques are very easy to use and produce strong bonds,
they have limited utility in in vivo targeting with nanocarriers due to
their potential immunogenicity and this restricts their repeated use
[326–328]. Research is currently underway to produce low immunoge-
nicity variations of streptavidin to allow continual use of this strategy in
therapeutics [326,328].
4.2.2. Homobifunctional linkers
In the late seventies, homobifunctional crosslinkers such as glutaral-
dehyde and dimethyl suberimidate were used for amine-amineFig. 4. Schematic design of a functionalized protocell. Tumor-targeting peptide ligands or reco
outer leaﬂet of the protocell lipid bilayer. Functionalized protocells can be loaded with a wid
composition of the lipid bilayer can be modiﬁed to regulate the concentration of bound pepti
and may also incorporate different polymer coatings (purple dots) to improve circulation retecrosslinking [329,330] to attach proteins or mannose ligands onto lipo-
somes [331]. Currently, this type of crosslinking is not widely used due
to possible homopolymerization during the reaction, which leads to ag-
gregates [332]. Moreover, since a majority of biological ligands contain
numerous amine groups, the use of homobifunctional linkers produces
a variety of targetingmoiety orientations, whichmay ultimately interfere
with speciﬁc targeting [303].
Crosslinkers can be used to stabilize direct disulﬁde bonds formed be-
tween a targeting moiety and a variety of nanocarriers. Conjugation be-
tween two thiols can be performed by reagents carrying halogens such
as bromobimane or bis-((N-iodoacetyl)piperazinyl)-sulfonerhodamine
that undergo nucleophilic substitution with thiols. The use of these
crosslinkers allows insertion of a ﬂuorescent probe between two
biological components [333,334], but has not yet been used to
label nanoparticles to our knowledge.
4.2.3. Heterobifunctional linkers
The use of heterobifunctional crosslinkers represents the future with
regards to linking targeting moieties to nanoparticles. These crosslinkers
facilitate conjugation reactions because they are available in a multitude
of different functional groups. Additionally, they incorporate PEG chains
that augment the solubility of nanocarriers in the physiological milieu,
thereby increasing end product stability. Three classes of reactions are
commonly used: amine to thiol, carboxylic acid to amine and click chem-
istry [335].mbinant human scFvs can be conjugated directly or indirectly to functional groups on the
e variety of cargos such as chemotoxins, genes, siRNA, aptamers or imaging agents. The
de ligands or scFvs to minimize binding site inhibition and optimize therapeutic indices,
ntion times.
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yl group to an amine. This reaction occurs in two stages, initially to create
EDC (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide) on the carboxyl
group that is present on the nanoparticle surface to form an intermediate
reactive species towards primary amines [336]. Recently, other conjuga-
tion methods introduced an N-hydroxysulfosuccinimide (NHS) linker in
a second step such as sulfo-NHS to produce a more stable intermediate
in order to improve reaction efﬁciency [337]. This approach was used to
attach siRNA onto gold nanoparticles to silence the c-myc protooncogene
in vitro and in vivo [338].
As described previously (see Section 4.1.1), cysteine residues at the
C- or N-terminus in numerous biomolecules can be utilized as function-
al moieties to conjugate targeting peptides or antibodies. Since nano-
particles can be easily modiﬁed to incorporate amines on their surface,
most heterobifunctional crosslinkers contain a NHS function on one
end to bind to amines, and on the other end tomaleimide to link to sulf-
hydryl groups. Heterobifunctional crosslinkers are water soluble, easy
to use, and the reactions are speciﬁc and produce high yields. One exam-
ple of this is the conjugation of the SP94 peptide to protocells containing
a drug cocktail to treat human hepatoma 3B cells [38]. Importantly,
these studies demonstrated speciﬁc delivery of SP94-protocells loaded
with high concentration drug cocktails, and long-term stability with
minimal non-speciﬁc binding and low toxicity to normal cells.
Finally, click chemistry can be employed with heterobifunctional
crosslinkers as well, using the same reactions detailed earlier (see
Section 4.1.2) namely, copper-catalyzed, copper-free, or TCO ligation.
Most commercially available crosslinkers include a PEG chain in their
backbone and allow the insertion of a new functional group by click
chemistry. The newly inserted functional group reacts with biomole-
cules through maleimide (Methyltetrazine-PEG4-maleimide, TCO-
PEG3-maleimide), carboxylic acid (DBCO-PEG4-Amine) or even amine
groups (Alkyne-PEG4-NHS Ester, Azido-PEG4-NHS Ester). Among re-
cent examples, liposomes containing dibenzocyclooctyl (DBCO)
labeled lipids were used to conjugate to tetraacetylated N-azidoacetyl-
d-mannosamine (Ac4ManNAz) ligands, which resulted in speciﬁc bind-
ing to A549 cells in vitro and to tumors in vivo [339].
5. Conclusion
The technological advances in peptide phage display and antibody
display, combined with the improved loading and biocompatibility of
sophisticated nanocarriers, should facilitate the production of modular,
targeted theranostic nanomedicines that speciﬁcally treat solid tumors
in the near future (Fig. 4). Conjugation of tumor-speciﬁc peptide ligands
or scFvs to the outer leaﬂet of the protocell lipid bilayer will depend on
the available functional groups and may require the use of homo- or
heterobifunctional crosslinkers. The orientation of the targeting moiety
can be constrained by adding a His6-Tag, a short α-helical E-coil or a
biotin group to the C-terminus for non-covalent association with NTA,
a shortα-helical K-coil or streptavidin, respectively, present on the sur-
face of the protocell. Additionally, the composition of the protocell lipid
bilayer may be adjusted to control the concentration of the targeting
moiety, increase its circulation retention time and promote endosomal
escape. Each protocell can be loaded with different types of imaging or
therapeutic agents depending on the clinical application. Compared to
conventional systemic chemotherapy, functionalized protocells present
a safe alternative that simultaneously permits real-time, non-invasive
imaging to monitor tumor growth inhibition. Taken together, these ad-
vantages provide greater clinical ﬂexibility to personalize treatment
regimens as dictated by treatment outcomes.
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